Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas.
<h4>Background</h4>Tamoxifen is still the most widely used drug in hormone therapy for the treatment of breast cancer. Its benefits in adjuvant treatment are well documented in controlled and randomized clinical studies, which have demonstrated an increase in disease-free intervals of pa...
Main Authors: | Valentina Folgiero, Paolo Avetrani, Giulia Bon, Selene E Di Carlo, Alessandra Fabi, Cecilia Nisticò, Patrizia Vici, Elisa Melucci, Simonetta Buglioni, Letizia Perracchio, Isabella Sperduti, Laura Rosanò, Ada Sacchi, Marcella Mottolese, Rita Falcioni |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2008-02-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18270579/?tool=EBI |
Similar Items
-
Analysis of ErbB Receptors: Regulation of ErbB-1 Kinase Activation and Localization of ErbB-4 to Membrane Microdomains
by: Thiel, Kristina Wyatt
Published: (2007) -
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
by: Guangyuan Li, et al.
Published: (2014-01-01) -
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
by: Diego Alvarado, et al.
Published: (2017-01-01) -
Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK.
by: Yong-Liang Yao, et al.
Published: (2013-01-01) -
ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
by: Meysam Moghbeli, et al.
Published: (2019-01-01)